Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride.
One hundred ninety-one hyperprolactinemic patients (78 women and 13 men; 54 with pituitary macroadenoma, 53 with microadenoma, and 84 with idiopathic disease) were treated for 2 to 48 months with one or two of the following prolactin (PRL)-lowering drugs: bromocriptine, metergoline, and lisuride. All of the three drugs used were highly effective in lowering PRL levels and restoring gonadal function both in females and in males in the majority of patients with either idiopathic or tumorous disease. In poorly responsive patients, increasing the drug doses resulted in further PRL lowering for all the three drugs. Mild side effects were frequently encountered with initiation of drug treatment but spontaneously subsided in most cases; severe side effects, necessitating stopping of the treatment, occurred in only 12 instances, but changing of the drug allowed PRL-lowering treatment to be continued in 11 of them.
D000236:Adenoma / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy; D006801:Humans; D008090:Lisuride / Q000627:therapeutic use*; D008297:Male; D008711:Metergoline / Q000627:therapeutic use*; D008875:Middle Aged; D010050:Ovarian Function Tests; D010911:Pituitary Neoplasms / Q000188:drug therapy; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*; D014794:Visual Fields / Q000187:drug effects
D004873:Ergolines; D008711:Metergoline; D001971:Bromocriptine; D011388:Prolactin; D008090:Lisuride